Results: 2

1.
Figure 2

Figure 2. From: A phase II pilot trial of low dose, continuous infusion, or "metronomic", paclitaxel and oral celecoxib in patients with metastatic melanoma.

Overall survival for the 20 patients on study. This includes 3 patients who were enrolled but did not start therapy.

R.S. Bhatt, et al. Cancer. ;116(7):1751-1756.
2.
Figure 1

Figure 1. From: A phase II pilot trial of low dose, continuous infusion, or "metronomic", paclitaxel and oral celecoxib in patients with metastatic melanoma.

Progression-free survival (PFS) for all 20 patients on trial. This includes 3 patients who were enrolled but did not start therapy.

R.S. Bhatt, et al. Cancer. ;116(7):1751-1756.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk